Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022.

  2. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    is contingent on further verification in confirmatory trials. … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval

  3. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    in December 2022 for the treatment of flares in adult patients with generalized pustular psoriasis. … It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

  4. Drug

    Bintrafusp alfa

    go.drugbank.com/drugs/DB15387
    Investigational

    Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer

  5. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    [A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the

  6. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.

  7. Drug

    Tolfenamic acid

    go.drugbank.com/drugs/DB09216
    Approved

    [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.

  8. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.

    Synonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride
  9. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963] … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  10. Drug

    Zinc gluconate

    go.drugbank.com/drugs/DB11248
    ApprovedInvestigationalVet approved

    More information about Zinc (in its natural form) is available at [DB01593]. … Studies show that zinc may be better absorbed in humans in the gluconate form [A32412], [L2105], however, results from other studies may vary.

    Mixtures: PEDIALYTE®30MEQ CON ZN, Children's Chew Multi & Min Tab